This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Soligenix’s 8K filing here.
Soligenix Company Profile
Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease.
See Also
- Five stocks we like better than Soligenix
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- 2 Defensive Energy Stocks to Hedge Against Trade Turmoil
- How to Invest in Biotech Stocks
- 3 Mining Stocks Poised to Ride the Precious Metals Boom
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Cybersecurity Stocks Are Soaring—Here’s Why These 3 Stand Out
